All In Biotech

Drug Trial Radar · NCT07117669

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ENP-501 in Non-Peanut Allergic Participants and Participants With a Known Peanut Allergy

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Dec 16, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
N-Fold, LLCIndustry
Sponsor type
Industry
Collaborators
CBCC Global Research
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)

Conditions

  • Peanut Allergy

Interventions

  • ENP-501Drug

    * Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose

  • PlaceboDrug

    * Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks * Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
  2. Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
  3. Number of Participants with Dose Limiting Toxicities (DLTs) as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
  4. Number of Participants with Systemic Reactions as Assessed by NCI CTCAE v 5.0 in Part 1Time frame: Up to 22 Weeks
  5. Number of Participants with changes in Clinical Laboratory Values in Part 1Time frame: Up to 22 Weeks
  6. Number of Participants with changes in Physical Examination in Part 1Time frame: Up to 22 Weeks
  7. Number of Participants with changes in Vital Signs in Part 1Time frame: Up to 22 Weeks
  8. Proportion of Participants Tolerating ≥1043 mg Cumulative Peanut Protein Without Dose-Limiting Symptoms at End of Treatment (EOT) Visit Double-Blind Placebo-Controlled Food Challenge (DBPCFC) Compared to Placebo in Part 2Time frame: Up to 72 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site 001

    Aurora, Colorado · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.